Proto-Oncogene Proteins c-myc

• 

  Subject Areas on Research

  • "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. 
  • A bayesian analysis strategy for cross-study translation of gene expression biomarkers. 
  • A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. 
  • A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice. 
  • A network of genetic events sufficient to convert normal human cells to a tumorigenic state. 
  • A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. 
  • A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. 
  • A statin-regulated microRNA represses human c-Myc expression and function. 
  • ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1. 
  • AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes. 
  • Activated α2-Macroglobulin Regulates Transcriptional Activation of c-MYC Target Genes through Cell Surface GRP78 Protein. 
  • Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. 
  • Activation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo. 
  • Adenovirus-mediated transfer of CCAAT/enhancer-binding protein-alpha identifies a dominant antiproliferative role for this isoform in hepatocytes. 
  • Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. 
  • Altered cytoplasmic/nuclear distribution of the c-myc protein in differentiating ML-1 human myeloid leukemia cells. 
  • Altered levels of prothymosin immunoreactive peptide, a growth-related gene product, during liver regeneration after chronic ethanol feeding. 
  • Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. 
  • An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. 
  • An animal model of MYC-driven medulloblastoma. 
  • An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. 
  • Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis. 
  • Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells. 
  • Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. 
  • Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway. 
  • Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. 
  • BET bromodomain inhibition of MYC-amplified medulloblastoma. 
  • Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. 
  • Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. 
  • C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. 
  • CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-α-Gabpa and stress-induced adaptive responses via NF-κB-cMYC. 
  • CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. 
  • Cadmium-induced DNA synthesis and cell proliferation in macrophages: the role of intracellular calcium and signal transduction mechanisms. 
  • Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. 
  • Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. 
  • Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis. 
  • Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. 
  • Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 
  • Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. 
  • Comparison of reprogramming efficiency between transduction of reprogramming factors, cell-cell fusion, and cytoplast fusion. 
  • Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies. 
  • Crystallization of a Complex Between MYC and Jas Motif. 
  • DNA CpG methylation inhibits binding of NF-kappa B proteins to the HIV-1 long terminal repeat cognate DNA motifs. 
  • Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. 
  • Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. 
  • Diffuse Large B-Cell Lymphoma Version 1.2016. 
  • Dissociation of thymidine incorporation and transferrin receptor expression from cell growth and c-myc accumulation in alpha-interferon-treated cells. 
  • Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control. 
  • Down-regulation of statin, a nonproliferation-specific nuclear protein, and up-regulation of c-myc after initiation of programmed cell death in mouse fibroblasts. 
  • Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. 
  • EndoU is a novel regulator of AICD during peripheral B cell selection. 
  • Essential roles of Caspase-3 in facilitating Myc-induced genetic instability and carcinogenesis. 
  • Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. 
  • Expression of c-fos in parietal endoderm, amnion and differentiating F9 teratocarcinoma cells. 
  • Family matters: How MYC family oncogenes impact small cell lung cancer. 
  • GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. 
  • Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. 
  • Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. 
  • Genetically engineered human cancer models utilizing mammalian transgene expression. 
  • Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 
  • Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. 
  • HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. 
  • HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. 
  • High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. 
  • Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. 
  • IRF4 addiction in multiple myeloma. 
  • Id3 Restricts γδ NKT Cell Expansion by Controlling Egr2 and c-Myc Activity. 
  • Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. 
  • Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. 
  • Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. 
  • Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. 
  • Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. 
  • Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. 
  • Integrated proteomic and transcriptomic profiling of mouse lung development and Nmyc target genes. 
  • Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors. 
  • LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. 
  • Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. 
  • MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. 
  • MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. 
  • MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. 
  • MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. 
  • MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. 
  • MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. 
  • MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. 
  • MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia. 
  • MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. 
  • MYC/BCL2 double-hit high-grade B-cell lymphoma. 
  • MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. 
  • Mammalian genes induce partially reprogrammed pluripotent stem cells in non-mammalian vertebrate and invertebrate species. 
  • Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients. 
  • Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. 
  • Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. 
  • Methionine metabolism is essential for SIRT1-regulated mouse embryonic stem cell maintenance and embryonic development. 
  • Multiple cell-type-specific elements regulate Myc protein stability. 
  • Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. 
  • Myc requires distinct E2F activities to induce S phase and apoptosis. 
  • N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. 
  • N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. 
  • N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. 
  • N-myc regulates parkin expression. 
  • Network calisthenics: control of E2F dynamics in cell cycle entry. 
  • Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation. 
  • Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells. 
  • Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. 
  • Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. 
  • Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. 
  • Polycystic kidney disease in SBM transgenic mice: role of c-myc in disease induction and progression. 
  • Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. 
  • Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. 
  • Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. 
  • Prospective associations of coronary heart disease loci in African Americans using the MetaboChip: the PAGE study. 
  • Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. 
  • Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. 
  • Rapid and Efficient Generation of Transgene-Free iPSC from a Small Volume of Cryopreserved Blood. 
  • Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. 
  • Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 
  • Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels. 
  • Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles. 
  • Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. 
  • Reverse engineering gene regulatory networks. 
  • Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. 
  • Sensing and integration of Erk and PI3K signals by Myc. 
  • Sequence specificity incompletely defines the genome-wide occupancy of Myc. 
  • Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background. 
  • ShcA regulates thymocyte proliferation through specific transcription factors and a c-Abl-dependent signaling axis. 
  • Skp2 regulates Myc protein stability and activity. 
  • Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. 
  • Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. 
  • TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. 
  • Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. 
  • Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis. 
  • The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. 
  • The Histone Methyltransferase Ash1l is Required for Epidermal Homeostasis in Mice. 
  • The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. 
  • The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. 
  • The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism. 
  • The winged-helix/forkhead protein myocyte nuclear factor beta (MNF-beta) forms a co-repressor complex with mammalian sin3B. 
  • Transcription interruption may be a common mechanism of c-myc regulation during HL-60 differentiation. 
  • Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy. 
  • Transcriptome regulation and chromatin occupancy by E2F3 and MYC in mice. 
  • Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. 
  • Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. 
  • Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. 
  • c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. 
  • c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection. 
  • c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts. 
  • c-Myc is required for maintenance of glioma cancer stem cells. 
  • c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. 
  • lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. 
  • p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study. 
• 

  Keywords of People

  • Buckley, Anne Frances, Assistant Professor of Pathology, Pathology
  • Hartemink, Alexander J., Professor in the Department of Computer Science, Biology
  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology